Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

César SerranoAdrián Mariño-EnríquezDerrick L TaoJulia KetzerGrant EilersMeijun ZhuChanning YuAristotle M MannanBrian P RubinGeorge D DemetriChandrajit P RautAjia PresnellArin McKinleyMichael C HeinrichJeffrey T CzaplinskiEwa SicinskaSebastian BauerSuzanne GeorgeJonathan A Fletcher

Published in: British journal of cancer (2019)

Our data highlight that heterogeneity of KIT secondary mutations is the main mechanism of tumour progression to KIT inhibitors in imatinib-resistant GIST patients. Therapeutic combinations of TKIs with complementary activity against resistant mutations may be useful to suppress growth of polyclonal imatinib-resistance in GIST.

Keyphrases

chronic myeloid leukemia
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
single cell
patient reported outcomes